{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:43:30Z","timestamp":1761561810266,"version":"3.40.5"},"reference-count":82,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Bristol-Myers Squibb Company"},{"name":"Pfizer Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Heart & Lung"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.hrtlng.2013.10.014","type":"journal-article","created":{"date-parts":[[2013,11,12]],"date-time":"2013-11-12T00:46:36Z","timestamp":1384217196000},"page":"48-59","source":"Crossref","is-referenced-by-count":22,"title":["Use of novel oral anticoagulants for patients with atrial fibrillation: Systematic review and clinical implications"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3619-966X","authenticated-orcid":false,"given":"Nancy M.","family":"Albert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hrtlng.2013.10.014_bib1","first-page":"e269","volume":"123","author":"Fuster","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib2","first-page":"e6","article-title":"Heart disease and stroke statistics\u20132013 update: a report from the American Heart Association","volume":"127","author":"Go","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.105.595140","article-title":"Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence","volume":"114","author":"Miyasaka","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib4","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa022913","article-title":"Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation","volume":"349","author":"Hylek","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib5","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham Study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"issue":"2 suppl","key":"10.1016\/j.hrtlng.2013.10.014_bib6","doi-asserted-by":"crossref","first-page":"e531S","DOI":"10.1378\/chest.11-2304","article-title":"Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"You","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib7","unstructured":"Boehringer Ingelheim. Pradaxa (dabigatran etexilate mesylate) Capsules Prescribing Information. Available at: http:\/\/bidocs.boehringer-ingelheim.com\/BIWebAccess\/ViewServlet.ser?docBase=renetnt&folderPath=\/Prescribing%20Information\/PIs\/Pradaxa\/Pradaxa.pdf; Accessed 02.05.13."},{"key":"10.1016\/j.hrtlng.2013.10.014_bib8","unstructured":"Bristol-Myers Squibb. Eliquis\u00ae (apixaban tablets) Prescribing Information. Available at: http:\/\/packageinserts.bms.com\/pi\/pi_eliquis.pdf; Accessed 04.02.13."},{"key":"10.1016\/j.hrtlng.2013.10.014_bib9","unstructured":"Janssen Pharmaceuticals Inc. Xarelto\u00ae (rivaroxaban tablets) Prescribing Information. Available at: http:\/\/www.xareltohcp.com\/sites\/default\/files\/pdf\/xarelto_0.pdf#zoom=100; Accessed 15.08.13."},{"key":"10.1016\/j.hrtlng.2013.10.014_bib10","unstructured":"Hall MJ, Levant S, DeFrances CJ. Hospitalization for Stroke in U.S. Hospitals, 1989-2009. NCHS Data Brief, No 95. Available at: http:\/\/www.cdc.gov\/nchs\/data\/databriefs\/db95.htm; Accessed 11.09.12."},{"key":"10.1016\/j.hrtlng.2013.10.014_bib11","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","article-title":"Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)","volume":"31","author":"Camm","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib12","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1161\/circ.114.4.257","volume":"114","author":"Fuster","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib13","doi-asserted-by":"crossref","first-page":"492","DOI":"10.7326\/0003-4819-131-7-199910050-00003","article-title":"Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis","volume":"131","author":"Hart","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib14","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"33","author":"Camm","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib15","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1378\/chest.10-2436","article-title":"Prognosis and guideline-adherent antithrombotic treatment in patients with atrial fibrillation and atrial flutter: implications of undertreatment and overtreatment in real-life clinical practice; the Loire Valley Atrial Fibrillation Project","volume":"140","author":"Gorin","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib16","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib17","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib18","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ahj.2005.04.017","article-title":"Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF)","volume":"151","author":"Gage","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib19","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1001\/archinte.159.5.457","article-title":"Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism","volume":"159","author":"Kuijer","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib20","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacc.2010.09.024","volume":"57","author":"Lip","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib21","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0002-9343(98)00198-3","article-title":"Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin","volume":"105","author":"Beyth","year":"1998","journal-title":"Am J Med"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib22","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A\u00a0novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib23","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1161\/01.STR.0000141933.75462.c2","article-title":"Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients","volume":"35","author":"Shireman","year":"2004","journal-title":"Stroke"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib24","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1378\/chest.12-0608","article-title":"Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a \u2018real world\u2019 anticoagulated atrial fibrillation population","volume":"143","author":"Roldan","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib25","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1161\/CIRCEP.111.967000","article-title":"Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation","volume":"5","author":"Gallego","year":"2012","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib26","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJM199211123272002","article-title":"Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators","volume":"327","author":"Ezekowitz","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib27","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(07)61233-1","article-title":"Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial","volume":"370","author":"Mant","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib28","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/CIRCULATIONAHA.109.934471","article-title":"Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF)","volume":"122","author":"Fonarow","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib29","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1161\/STROKEAHA.108.516344","article-title":"Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated","volume":"40","author":"Gladstone","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib30","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.jacc.2009.04.091","article-title":"Quality of care for atrial fibrillation among patients hospitalized for heart failure","volume":"54","author":"Piccini","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib31","unstructured":"Bristol-Myers Squibb. Coumadin Prescribing Information. Available at: http:\/\/packageinserts.bms.com\/pi\/pi_coumadin.pdf; Accessed 12.04.12."},{"key":"10.1016\/j.hrtlng.2013.10.014_bib32","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archinte.167.3.239","article-title":"Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V","volume":"167","author":"White","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib33","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib34","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib35","unstructured":"Boehringer Ingelheim International GmbH. Pradaxa\u00ae (INN \u2013 dabigatran etexilate) Summary of Product Characteristics. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000829\/WC500041059.pdf; Accessed 28.09.11."},{"key":"10.1016\/j.hrtlng.2013.10.014_bib36","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejim.2008.04.005","article-title":"INR variability in atrial fibrillation: a risk model for cerebrovascular events","volume":"20","author":"Amouyel","year":"2009","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib37","doi-asserted-by":"crossref","first-page":"160S","DOI":"10.1378\/chest.08-0670","article-title":"Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-based Clinical Practice Guidelines (8th edition)","volume":"133","author":"Ansell","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib38","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1161\/CIRCULATIONAHA.112.101808","volume":"126","author":"Van Spall","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib39","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1111\/j.1538-7836.2010.03996.x","article-title":"Patient characteristics associated with oral anticoagulation control: results of the Veterans Affairs Study to Improve Anticoagulation (VARIA)","volume":"8","author":"Rose","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib40","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1161\/CIRCULATIONAHA.107.750000","article-title":"Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range","volume":"118","author":"Connolly","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib41","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.amjmed.2009.11.025","article-title":"Underuse of oral anticoagulants in atrial fibrillation: a systematic review","volume":"123","author":"Ogilvie","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib42","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/ageing\/afr097","article-title":"Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review","volume":"40","author":"Pugh","year":"2011","journal-title":"Age Ageing"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib43","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1747-4949.2011.00667.x","article-title":"Underuse of antithrombotic therapy caused high incidence of ischemic stroke in patients with atrial fibrillation","volume":"7","author":"Yu","year":"2012","journal-title":"Int J Stroke"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib44","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2318-12-14","article-title":"Use of warfarin in long-term care: a systematic review","volume":"12","author":"Neidecker","year":"2012","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib45","doi-asserted-by":"crossref","first-page":"970","DOI":"10.7326\/0003-4819-124-11-199606010-00004","article-title":"The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics","volume":"124","author":"Fihn","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib46","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.amjcard.2011.09.023","article-title":"Effect of warfarin on outcomes in septuagenarian patients with atrial fibrillation","volume":"109","author":"Roy","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib47","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.amjmed.2012.01.033","article-title":"Risk of falls and major bleeds in patients on oral anticoagulation therapy","volume":"125","author":"Donze","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib48","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/archinte.163.13.1580","article-title":"Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians' fears often unfounded","volume":"163","author":"Man-Son-Hing","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib49","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1468-1331.2012.03804.x","article-title":"Stroke due to atrial fibrillation in a population-based stroke registry (Ludwigshafen Stroke Study) CHADS(2), CHA(2) DS(2)-VASc score, underuse of oral anticoagulation, and implications for preventive measures","volume":"20","author":"Palm","year":"2013","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib50","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/ageing\/afl129","article-title":"A\u00a0randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO)","volume":"36","author":"Rash","year":"2007","journal-title":"Age Ageing"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib51","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1161\/STR.0b013e318266722a","article-title":"Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"43","author":"Furie","year":"2012","journal-title":"Stroke"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib52","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1161\/CIR.0b013e31820f14c0","article-title":"2011 ACCF\/AHA\/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"123","author":"Wann","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib53","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib54","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib55","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.amjcard.2012.03.049","article-title":"Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation","volume":"110","author":"Miller","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib56","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/S0140-6736(12)60986-6","article-title":"Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial","volume":"380","author":"Lopes","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib57","doi-asserted-by":"crossref","first-page":"973","DOI":"10.3949\/ccjm.70.11.973","article-title":"When patients on warfarin need surgery","volume":"70","author":"Jaffer","year":"2003","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib58","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/j.1365-2753.2012.01886.x","article-title":"Factors influencing doctors' selection of dabigatran in non-valvular atrial fibrillation","volume":"19","author":"Huang","year":"2013","journal-title":"J\u00a0Eval Clin Pract"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib59","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMc1007378","article-title":"Newly identified events in the RE-LY trial","volume":"363","author":"Connolly","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib60","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1161\/STROKEAHA.112.652065","article-title":"Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal","volume":"43","author":"Dowlatshahi","year":"2012","journal-title":"Stroke"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib61","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1161\/STROKEAHA.112.650614","article-title":"Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial","volume":"43","author":"Hart","year":"2012","journal-title":"Stroke"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib62","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1023\/A:1018714626726","article-title":"Temporary reversal of anticoagulation using oral vitamin K","volume":"10","author":"White","year":"2000","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib63","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jacc.2012.03.019","article-title":"Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation","volume":"60","author":"Lip","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib64","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1161\/CIRCOUTCOMES.112.965988","article-title":"Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation","volume":"5","author":"Schneeweiss","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib65","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1161\/CIRCOUTCOMES.112.966572","article-title":"Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation","volume":"5","author":"Baker","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib66","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1160\/TH12-02-0093","article-title":"An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation","volume":"108","author":"Mantha","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib67","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/qjmed\/hcs114","article-title":"Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation","volume":"105","author":"Testa","year":"2012","journal-title":"QJM"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib68","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1161\/STROKEAHA.111.641027","article-title":"Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack","volume":"43","author":"Kamel","year":"2012","journal-title":"Stroke"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib69","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.amjcard.2012.05.011","article-title":"Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation","volume":"110","author":"Lee","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib70","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1161\/CIRCOUTCOMES.112.965251","article-title":"Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin","volume":"5","author":"Lee","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib71","first-page":"776","article-title":"Medical cost reductions associated with the usage of novel oral anticoagulants vs. warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF and ARISTOTLE trials","volume":"15","author":"Deitelzweig","year":"2012","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib72","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/clpt.2013.83","article-title":"Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation","volume":"94","author":"Pink","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib73","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation (Supplementary Appendix)","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib74","first-page":"520","article-title":"Reversal of apixaban induced alterations of hemostasis by different coagulation factor concentrates: studies in\u00a0vitro with circulating human blood","volume":"126","author":"Escolar","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib75","unstructured":"Clinicaltrials.gov. Phase 2 healthy volunteer study to evaluate the ability of PRT064445 to reverse the effects of several blood thinner drugs on laboratory tests. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT01758432?term=PRT064445&rank=1; Accessed 04.01.13."},{"key":"10.1016\/j.hrtlng.2013.10.014_bib76","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood-2012-11-468207","article-title":"A\u00a0specific antidote for dabigatran: functional and structural characterization","volume":"121","author":"Schiele","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib77","unstructured":"Bayer Healthcare AG. Xarelto\u00ae (rivaroxaban) Prescribing Information. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/202439s001lbl.pdf; Accessed 06.02.13."},{"issue":"Abstract Supplement","key":"10.1016\/j.hrtlng.2013.10.014_bib78","first-page":"685","article-title":"Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial (abstract 4045)","volume":"33","author":"Granger","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib79","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jacc.2012.09.057","volume":"61","author":"Patel","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib80","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1161\/STROKEAHA.111.624650","article-title":"Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran","volume":"42","author":"Zhou","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib81","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","article-title":"Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects","volume":"124","author":"Eerenberg","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.hrtlng.2013.10.014_bib82","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/JCN.0b013e31820019b9","article-title":"Living with atrial fibrillation: a qualitative study","volume":"26","author":"McCabe","year":"2011","journal-title":"J\u00a0Cardiovasc Nurs"}],"container-title":["Heart & Lung"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0147956313003701?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0147956313003701?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T10:27:54Z","timestamp":1716114474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0147956313003701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0147956313003701"],"URL":"https:\/\/doi.org\/10.1016\/j.hrtlng.2013.10.014","relation":{},"ISSN":["0147-9563"],"issn-type":[{"type":"print","value":"0147-9563"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}